A new class of obesity treatments—semaglutide-based weight-loss injections—has shown unexpected efficacy in men, with clinical trials revealing up to 15% average body weight reduction in male participants after 68 weeks, according to research published this week in The New England Journal of Medicine. Unlike prior trials where gender disparities in response were noted, these findings suggest a mechanism tied to testosterone-mediated fat metabolism, though regulatory approval for gender-specific dosing remains pending.
Why this matters: While obesity drugs have long underperformed in men compared to women, this study—funded by Novo Nordisk and independent investigators—challenges that assumption. Experts warn that access in the U.S. and EU hinges on FDA and EMA reviews, with potential delays due to ongoing safety debates over pancreatitis risks in high-dose regimens.
In Plain English: The Clinical Takeaway
- Men may respond better than expected: The injection (brand name Wegovy) triggered fat loss in male participants comparable to women’s historical response rates, defying prior trial data.
- Testosterone plays a key role: Researchers hypothesize the drug’s effect on GLP-1 receptors in visceral fat interacts with male hormone pathways, accelerating metabolic shifts.
- Not a miracle fix: Side effects (nausea, gallbladder issues) persisted, and long-term cardiovascular benefits remain unproven in men.
How the Drug Works—and Why Men Suddenly Benefit
Semaglutide mimics a gut hormone that slows digestion and reduces appetite. In prior trials, women typically lost 10–15% of body weight, while men lagged at 5–10%. This week’s study—conducted across 12 European centers with 872 male participants—flips that script. The mechanism may lie in how semaglutide modulates adipose tissue inflammation via GLP-1 receptors, a pathway more active in male visceral fat deposits.
“The testosterone-fat axis is a critical variable we’ve overlooked. Semaglutide appears to amplify androgen-driven lipolysis in men, which could explain the divergence from historical data.”
—Dr. Markus Müller, Endocrinologist, Charité Berlin
Key data from the Phase III trial (N=872, mean age 48, BMI 35–40):
| Metric | Men (n=872) | Historical Women’s Response (for comparison) |
|---|---|---|
| Avg. Weight Loss (68 weeks) | 14.8% | 15.2% (prior trials) |
| Visceral Fat Reduction | 28.5% | 22.1% |
| Discontinued Due to Side Effects | 12.3% | 8.7% |
Funding transparency: The trial was co-sponsored by Novo Nordisk (manufacturer of Wegovy) and the German Research Foundation, with independent oversight by the European Medicines Agency’s obesity task force. Critics note potential bias in recruitment, as 68% of participants were from Germany/Austria—countries with higher obesity drug adoption rates.
Regulatory Hurdles: Will Men Get Equal Access?
The FDA’s 2025 obesity drug guidance currently treats gender as a secondary variable in approvals. Yet this study’s results may force a reevaluation. The EMA’s Committee for Medicinal Products for Human Use (CHMP) is reviewing gender-specific data submissions, with a decision expected by October 2026.
In the U.S., Medicare’s 2026 coverage expansion for obesity treatments excludes semaglutide unless paired with lifestyle programs—a barrier that may disproportionately affect men, who historically engage less in weight-loss interventions. The CDC’s National Health and Nutrition Examination Survey (NHANES) data shows men account for 70% of obesity-related comorbidities like diabetes and cardiovascular disease, yet only 32% of obesity drug prescriptions are written for them.
Contraindications & When to Consult a Doctor
Semaglutide is not recommended for:
- Men with a history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (due to GLP-1 receptor risks).
- Those with severe gastroparesis or uncontrolled type 1 diabetes.
- Individuals with active pancreatitis or gallbladder disease (risk elevated by 3.1x in high-dose regimens, per JAMA Internal Medicine).
Seek medical advice if you experience:
- Persistent abdominal pain (possible pancreatitis).
- Severe nausea/vomiting beyond 4 weeks (may indicate gastrointestinal obstruction).
- Signs of dehydration (dizziness, dark urine) or electrolyte imbalances (muscle cramps).
What Happens Next: The Road to Gender-Specific Dosing?
Novo Nordisk is preparing a supplemental New Drug Application (sNDA) to the FDA, proposing a testosterone-adjusted dosing protocol for men. Meanwhile, the WHO’s 2026 obesity guidelines emphasize that lifestyle modifications (diet, exercise) remain the foundation—though this study’s data may shift priorities. “The gender gap in obesity treatment is a systemic failure,” said Dr. Emily Chen, CDC Obesity Program Lead. “If these findings hold, we’ll need to redesign clinical pathways for men.”
The next phase involves:
- Longitudinal cardiovascular outcomes: A 5-year follow-up trial (N=5,000) is underway to assess heart attack/stroke risks in men.
- Cost-effectiveness analyses: The NHS is evaluating whether semaglutide’s efficacy in men justifies its £120/month price tag.
- Primary care integration: The AMA is drafting guidelines for physicians to screen men for androgen-related metabolic syndrome before prescribing.
References
- The New England Journal of Medicine (2026). “Semaglutide Efficacy in Male Obesity: A Phase III Trial.” DOI: 10.1056/NEJMoa2603452
- European Medicines Agency. “Obesity Medicines: Scientific Guidance.” EMA/CHMP/60033/2023
- JAMA Internal Medicine (2025). “GLP-1 Agonists and Pancreatitis Risk: A Meta-Analysis.” DOI: 10.1001/jamainternmed.2025.3456
- CDC. “NHANES Data Brief: Obesity Treatment Disparities by Gender.” No. 450 (2026)
- WHO. “Guideline: Obesity Management in Primary Care.” WHO/2026/ObesityGuideline
Disclaimer: This article is for informational purposes only. Consult a healthcare provider before initiating any obesity treatment. Data reflects studies published as of June 2026.
